As debates over the safety and regulation of kratom intensify across the United States, Rhode Island stands at a pivotal juncture. House Bill 5565, which recently passed the state House, aims to ban synthetic kratom products while preserving access to natural, regulated kratom for adults. This legislative move reflects a growing consensus among scientists, policymakers, and consumer advocates: the greatest risks associated with kratom stem not from the natural plant, but from adulterated and synthetic analogs that can pose significant public health dangers.
Understanding Kratom: The Plant and Its Uses
Kratom (Mitragyna speciosa) is a tropical tree native to Southeast Asia. Its leaves have been traditionally used for centuries to manage pain, increase energy, and as a mild stimulant. In the U.S., kratom is available in various forms—powder, capsules, teas—and is commonly used by individuals seeking relief from chronic pain, anxiety, or as an aid in reducing opioid dependence through traditional use.
The plant’s primary active compounds, mitragynine and 7-hydroxymitragynine, interact with opioid receptors in the brain, but their pharmacological profile differs substantially from classical opioids. Mitragynine acts as a partial agonist, which means it produces less pronounced effects than full opioid agonists like morphine, and is associated with a lower risk of respiratory depression—a major cause of opioid overdose deaths, as detailed in pharmacological studies.
The Real Risk: Synthetic and Adulterated Kratom Products
While kratom’s natural forms have been the subject of increasing scientific scrutiny, the real danger lies in synthetic and adulterated products masquerading as kratom. These can include high-concentration extracts, especially those with elevated levels of 7-hydroxymitragynine, or products laced with other novel psychoactive substances (NPS), as reported by the National Poison Data System.
Reports from the U.S. Food and Drug Administration reveal that many adverse events—including hospitalizations and deaths—linked to “kratom” actually involve products contaminated with other substances or used in combination with other drugs. The FDA’s own data show that mitragynine toxicity was the sole cause of death in only a minority of cases; most incidents involved polydrug use or adulterated products, making it difficult to attribute harm directly to pure kratom.
This distinction is crucial. As noted in a recent Providence Journal opinion piece, the proliferation of synthetic analogs and adulterated products has distorted public perception of kratom’s safety profile. These products, often engineered for heightened psychoactive effects, bear little resemblance to the traditional plant and are the primary focus of regulatory efforts like Rhode Island’s HB 5565.
Scientific Consensus: What the Research Says
Over the past decade, kratom science has expanded dramatically, with more than 450 new scientific publications addressing its safety, pharmacology, and potential benefits. The National Institute on Drug Abuse (NIDA) has invested over $100 million in kratom research and has consistently advocated for regulation rather than prohibition.
NIDA Director Nora Volkow has testified before Congress that kratom should be regulated appropriately, not banned, and has highlighted promising research into its potential as a safer alternative for pain management and opioid use disorder, as outlined in congressional testimony. Importantly, NIDA’s review of FDA claims about kratom-related deaths found that most were attributable to adulterated products or polydrug use, not kratom itself.
A recent FDA pilot study further supports the relative safety of natural kratom. Conducted under controlled conditions, the study found that kratom was well tolerated at a range of doses, with vomiting as the most common adverse effect at higher doses. No serious adverse events were reported, and the study concluded that, at least in its botanical form, kratom does not present the same risks as classical opioids.
Regulatory Approaches: The Rise of Consumer Protection Acts
In response to the risks posed by adulterated and synthetic kratom products, several states have enacted or are considering Kratom Consumer Protection Acts. These laws establish clear guidelines for manufacturing, labeling, and selling kratom, and set age restrictions to prevent access by minors.
For example, Texas law requires kratom products to be properly labeled, prohibits adulteration with dangerous substances, limits the concentration of 7-hydroxymitragynine, and bans synthetic alkaloids. Retailers cannot sell kratom to individuals under 18, and violations carry criminal and civil penalties. Similar measures are in place or under consideration in states like Colorado, Illinois, and Pennsylvania.
Rhode Island’s HB 5565 follows this model, banning synthetic and adulterated kratom products, requiring proper labeling, and imposing age restrictions to ensure only adults can purchase kratom. The bill aims to strike a balance between protecting consumers from dangerous products and preserving access to natural kratom for those who benefit from its use.
The FDA and Kratom: An Evolving Stance
The FDA has long expressed concerns about kratom, warning consumers about its potential for abuse and adverse events. However, the agency has not classified kratom as a controlled substance, and its own recent research suggests that kratom, in its natural form, may be less dangerous than previously thought.
The FDA’s Center for Food Safety and Applied Nutrition (CFSAN) continues to monitor adverse event reports, but acknowledges limitations in the data—particularly the difficulty in establishing causality and the prevalence of polydrug use in reported cases. The agency has also recognized the need for further research to fully understand kratom’s effects and potential risks.
Consumer Perspectives and Public Health
Millions of Americans use kratom, including seniors managing chronic pain, veterans coping with trauma, and individuals seeking alternatives to prescription opioids. Many report that kratom has helped them reduce or eliminate opioid use, improve quality of life, and regain functionality lost to pain or addiction.
While some users do experience dependence, experts caution against conflating this with the dangerous addiction associated with classical opioids. As noted by the World Health Organization’s Expert Committee on Drug Dependence, there is limited evidence of abuse liability in humans, and more research is needed to clarify kratom’s risk profile.
The Path Forward: Sensible Regulation Over Prohibition
The evidence is clear: the primary public health threat comes from adulterated and synthetic kratom products, not from the natural plant itself. Regulatory frameworks like Rhode Island’s HB 5565 and the various Kratom Consumer Protection Acts provide a blueprint for safeguarding consumers while preserving access to a plant that, for many, offers a lifeline away from more dangerous substances.
As research continues and the regulatory landscape evolves, it is essential that policymakers base their decisions on sound science, not sensationalism. Sensible regulation—focused on product purity, accurate labeling, and age restrictions—offers the best path forward for protecting public health while respecting the choices of responsible adult consumers.
For more on the arguments behind Rhode Island’s approach, see the original Providence Journal opinion piece.